Effect of 4-AP on MPP+/ MPTP-induced Parkinson's disease model

Qiongwen Rong1, Chang Zhou1, Yuanyuan Ma1

  • 1Department of Neurology, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, 570102, China. 13907580113@163.com.

Insights

4-Aminopyridine (4-AP) did not improve motor function in Parkinson

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cell Biology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction.
  • MPP+ and MPTP are commonly used neurotoxins to induce Parkinsonian models in vitro and in vivo.
  • 4-Aminopyridine (4-AP) is a potassium channel blocker with potential neuroprotective effects.

Purpose of the Study:

  • To investigate the therapeutic potential of 4-Aminopyridine (4-AP) in cellular and animal models of Parkinson's disease (PD).
  • To evaluate the effect of 4-AP on cell viability, motor function, and dopaminergic neuron survival in PD models.

Main Methods:

  • Parkinson's disease cell models were established using MPP+ and treated with varying concentrations of 4-AP.
  • Cell viability was assessed using the CCK8 assay.
  • Parkinson's disease mouse models were induced by MPTP and subsequently treated with 4-AP for 10 days.
  • Behavioral tests (pole climbing, open field) and immunohistochemistry (IHC)/Western blot (WB) for tyrosine hydroxylase (TH) expression were performed.

Main Results:

  • 4-AP increased the viability of MPP+-induced Parkinson's disease cells.
  • In MPTP-induced Parkinson's disease mice, 4-AP did not improve spontaneous activity or pole climbing times compared to untreated PD mice.
  • Both PD mice and 4-AP treated PD mice showed reduced midbrain TH expression compared to normal mice; 4-AP did not prevent this reduction.

Conclusions:

  • 4-AP pretreatment may reduce the toxicity of MPP+ in cell models.
  • 4-AP does not ameliorate motor deficits or protect dopaminergic neurons in MPTP-induced Parkinson's disease models.
  • The timing of intervention (pre-treatment vs. post-intervention) is critical for therapeutic efficacy in Parkinson's disease models.